胃腺癌的临床病理特征和生存结果:真实世界的单中心数据。

IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY
Indian Journal of Gastroenterology Pub Date : 2024-12-01 Epub Date: 2023-11-10 DOI:10.1007/s12664-023-01455-4
L Charles, Archana Elangovan, Yadav Nisha, Esha Jafa, Vikram Kate, Sandhiya Selvarajan, Smita Kayal, Rajesh Nachiappa Ganesh, Biswajit Dubashi, Prasanth Penumadu, Prasanth Ganesan
{"title":"胃腺癌的临床病理特征和生存结果:真实世界的单中心数据。","authors":"L Charles, Archana Elangovan, Yadav Nisha, Esha Jafa, Vikram Kate, Sandhiya Selvarajan, Smita Kayal, Rajesh Nachiappa Ganesh, Biswajit Dubashi, Prasanth Penumadu, Prasanth Ganesan","doi":"10.1007/s12664-023-01455-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer is the fifth most-common cancer and fourth common cause for cancer-related deaths globally. Surgery preceded or followed by chemotherapy or chemoradiotherapy is considered an optimal treatment for locally advanced gastric cancer. This study is a real-world data from a tertiary referral institute in southern India, in its experience with treating gastric adenocarcinoma over a period of four years with a minimum of two-year follow-up.</p><p><strong>Methods: </strong>This was a retrospective analysis of data of patients with histologically proven gastric adenocarcinoma enrolled in the Department of Medical Oncology from 2015 to 2018. The demographic details, presentation, staging, treatment received and outcomes of patients with gastric adenocarcinoma were collected and analyzed in this study.</p><p><strong>Results: </strong>Total 488 patients with gastric adenocarcinoma were included for the study. The stage-wise distribution of patients revealed early and locally advanced (45%) and metastatic (55%). The peritoneum and liver were the common sites of metastasis. The treatment distribution of these patients included perioperative chemotherapy followed by surgery (25 [5%]), surgery followed by adjuvant chemotherapy (65 [13%]), surgery alone (16 [3%]), perioperative chemotherapy alone (23 [4%]), palliative chemotherapy (274 [56%]) and supportive care (85 [17%]). The median overall survival for curative, palliative and supportive treatment was 23 (18-28), nine (7.6-10.4) and four (2.7-5.3) months, respectively. The two-year overall survival in the intention to treat population in the primary surgery (n = 81) and perioperative chemotherapy groups (n = 66) was 67.4% vs. 29.9% (p < 0.0001), respectively.</p><p><strong>Conclusion: </strong>This study highlights the advanced nature of the presentation of gastric cancer patients and the poor rate of treatment completion. The median survival rates in curative patients remain to be dismally poor. The treatment sequence in curable gastric cancer of surgery followed by adjuvant chemotherapy vs. perioperative chemotherapy followed by surgery needs to be explored in our country.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinicopathological features and survival outcomes for gastric adenocarcinoma: Real-world single-center data.\",\"authors\":\"L Charles, Archana Elangovan, Yadav Nisha, Esha Jafa, Vikram Kate, Sandhiya Selvarajan, Smita Kayal, Rajesh Nachiappa Ganesh, Biswajit Dubashi, Prasanth Penumadu, Prasanth Ganesan\",\"doi\":\"10.1007/s12664-023-01455-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Gastric cancer is the fifth most-common cancer and fourth common cause for cancer-related deaths globally. Surgery preceded or followed by chemotherapy or chemoradiotherapy is considered an optimal treatment for locally advanced gastric cancer. This study is a real-world data from a tertiary referral institute in southern India, in its experience with treating gastric adenocarcinoma over a period of four years with a minimum of two-year follow-up.</p><p><strong>Methods: </strong>This was a retrospective analysis of data of patients with histologically proven gastric adenocarcinoma enrolled in the Department of Medical Oncology from 2015 to 2018. The demographic details, presentation, staging, treatment received and outcomes of patients with gastric adenocarcinoma were collected and analyzed in this study.</p><p><strong>Results: </strong>Total 488 patients with gastric adenocarcinoma were included for the study. The stage-wise distribution of patients revealed early and locally advanced (45%) and metastatic (55%). The peritoneum and liver were the common sites of metastasis. The treatment distribution of these patients included perioperative chemotherapy followed by surgery (25 [5%]), surgery followed by adjuvant chemotherapy (65 [13%]), surgery alone (16 [3%]), perioperative chemotherapy alone (23 [4%]), palliative chemotherapy (274 [56%]) and supportive care (85 [17%]). The median overall survival for curative, palliative and supportive treatment was 23 (18-28), nine (7.6-10.4) and four (2.7-5.3) months, respectively. The two-year overall survival in the intention to treat population in the primary surgery (n = 81) and perioperative chemotherapy groups (n = 66) was 67.4% vs. 29.9% (p < 0.0001), respectively.</p><p><strong>Conclusion: </strong>This study highlights the advanced nature of the presentation of gastric cancer patients and the poor rate of treatment completion. The median survival rates in curative patients remain to be dismally poor. The treatment sequence in curable gastric cancer of surgery followed by adjuvant chemotherapy vs. perioperative chemotherapy followed by surgery needs to be explored in our country.</p>\",\"PeriodicalId\":13404,\"journal\":{\"name\":\"Indian Journal of Gastroenterology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12664-023-01455-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12664-023-01455-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:癌症是全球第五大最常见的癌症和第四大癌症相关死亡原因。在化疗或放化疗之前或之后进行手术被认为是局部晚期癌症的最佳治疗方法。这项研究是来自印度南部一家三级转诊研究所的真实世界数据,该研究所在四年内治疗胃腺癌的经验,至少有两年的随访。方法:这是对2015年至2018年在医学肿瘤科登记的经组织学证实的胃腺癌患者的数据进行的回顾性分析。本研究收集并分析了胃腺癌患者的人口统计学细节、表现、分期、接受的治疗和结果。结果:共有488例胃腺癌患者纳入研究。患者的分期分布显示早期和局部晚期(45%)以及转移性(55%)。腹膜和肝脏是常见的转移部位。这些患者的治疗分布包括围手术期化疗后手术(25[5])、手术后辅助化疗(65[13%])、单独手术(16[3%])、围手术期单独化疗(23[4])、姑息性化疗(274[56%])和支持性护理(85[17%])。治疗性、姑息性和支持性治疗的中位总生存期分别为23个月(18-28)、9个月(7.6-10.4)和4个月(2.7-5.3)。意向治疗人群在初次手术中的两年总生存率(n = 81)和围手术期化疗组(n = 66)分别为67.4%和29.9%(p 结论:本研究突出了癌症患者表现的先进性和较差的治疗完成率。治愈患者的中位生存率仍然很低。手术后辅助化疗与围手术期化疗后手术治疗癌症的治疗顺序有待我国进一步探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinicopathological features and survival outcomes for gastric adenocarcinoma: Real-world single-center data.

Introduction: Gastric cancer is the fifth most-common cancer and fourth common cause for cancer-related deaths globally. Surgery preceded or followed by chemotherapy or chemoradiotherapy is considered an optimal treatment for locally advanced gastric cancer. This study is a real-world data from a tertiary referral institute in southern India, in its experience with treating gastric adenocarcinoma over a period of four years with a minimum of two-year follow-up.

Methods: This was a retrospective analysis of data of patients with histologically proven gastric adenocarcinoma enrolled in the Department of Medical Oncology from 2015 to 2018. The demographic details, presentation, staging, treatment received and outcomes of patients with gastric adenocarcinoma were collected and analyzed in this study.

Results: Total 488 patients with gastric adenocarcinoma were included for the study. The stage-wise distribution of patients revealed early and locally advanced (45%) and metastatic (55%). The peritoneum and liver were the common sites of metastasis. The treatment distribution of these patients included perioperative chemotherapy followed by surgery (25 [5%]), surgery followed by adjuvant chemotherapy (65 [13%]), surgery alone (16 [3%]), perioperative chemotherapy alone (23 [4%]), palliative chemotherapy (274 [56%]) and supportive care (85 [17%]). The median overall survival for curative, palliative and supportive treatment was 23 (18-28), nine (7.6-10.4) and four (2.7-5.3) months, respectively. The two-year overall survival in the intention to treat population in the primary surgery (n = 81) and perioperative chemotherapy groups (n = 66) was 67.4% vs. 29.9% (p < 0.0001), respectively.

Conclusion: This study highlights the advanced nature of the presentation of gastric cancer patients and the poor rate of treatment completion. The median survival rates in curative patients remain to be dismally poor. The treatment sequence in curable gastric cancer of surgery followed by adjuvant chemotherapy vs. perioperative chemotherapy followed by surgery needs to be explored in our country.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Indian Journal of Gastroenterology
Indian Journal of Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
3.90
自引率
10.00%
发文量
73
期刊介绍: The Indian Journal of Gastroenterology aims to help doctors everywhere practise better medicine and to influence the debate on gastroenterology. To achieve these aims, we publish original scientific studies, state-of -the-art special articles, reports and papers commenting on the clinical, scientific and public health factors affecting aspects of gastroenterology. We shall be delighted to receive articles for publication in all of these categories and letters commenting on the contents of the Journal or on issues of interest to our readers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信